Multicenter Phase-II-Study with Capecitabine/Trastuzumab as first-line therapy for advanced HER2-overexpressing pancreas carcinoma.
Phase of Trial: Phase II
Latest Information Update: 06 Jul 2012
At a glance
- Drugs Capecitabine; Trastuzumab
- Indications Pancreatic cancer
- Focus Therapeutic Use
- 06 Jul 2012 Actual end date (May 2008) added as reported by German Clinical Trials Register record.
- 25 Aug 2011 New source identified and integrated (German Clinical Trials Register record DRKS00000600).
- 08 Dec 2008 Status changed from active, no longer recruiting to completed.